September 9, 2021

African American, Hispanic American race/ethnicity associated with greater disability, symptom severity in multiple sclerosis For patients with multiple sclerosis (MS), African American (AA) and Hispanic American (HA) race/ethnicity is associated with higher overall disability and higher symptom severity versus Whites, according to a study published online May 28 in Neurology: Clinical Practice. Ilya Kister, M.D.,...

While multiple sclerosis can cause a wide swath of symptoms and challenges for anyone diagnosed with the autoimmune disease, a new study finds that race may play a role in disease severity. Researchers discovered that Black individuals with MS may be more severely affected by the disease, but also that this added impact persisted even...

Black Americans with multiple sclerosis (MS) experience a higher disease burden than White patients, according to a study published online June 30 in Neurology. Karla Gray-Roncal, M.D., from the Johns Hopkins University in Baltimore, and colleagues compared MS characteristics including self-reported disability, objective neurologic function assessments, and quantitative brain magnetic resonance imaging (MRI) measurements for...

A new study may help explain why people with multiple sclerosis (MS) experience worsening disability while those with two related diseases do not. MS causes permanent brain and spinal cord scarring, and researchers investigated whether the same damage accompanies two rarer, similar diseases in which the immune system also attacks the central nervous system. The...

The U.S. Food and Drug Administration has approved the first oral, at-home drug for spinal muscular atrophy (SMA), the agency announced in early August 2021. Evrysdi (risdiplam) was approved to treat patients ages 2 months and older with SMA and is the third drug approved for the disease. The drug is administered daily at home...